Evidence map›Paper›PMID 34575693›Full record

ArticleJournal of personalized medicine2021

Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?

Nora Pashayan, Antonis C Antoniou, Andrew Lee, Michael Wolfson, Jocelyne Chiquette, Laurence Eloy, Andrea Eisen, Tracy L Stockley, Hermann Nabi, Jennifer D Brooks and 5 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nora PashayanDepartment of Applied Health Research, University College London, London WC1E 7HB, UK.ORCID 0000-0003-0843-2468
Antonis C AntoniouCentre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.ORCID 0000-0001-9223-3116
Andrew LeeCentre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.
Michael WolfsonSchool of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
Jocelyne ChiquetteDepartment of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Quebec City, QC G1V 4G2, Canada.
Laurence EloyQuebec Cancer Program, Ministère de la Santé et des Services Sociaux, Quebec City, QC G1S 2M1, Canada.
Andrea EisenSunnybrook Health Science Centre, Toronto, ON M4N 3M5, Canada.
Tracy L StockleyDivision Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON M5G 2C4, Canada.ORCID 0000-0002-4476-9722
Hermann NabiCHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.
Jennifer D BrooksDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.ORCID 0000-0001-7574-4256
Michel DorvalCHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.ORCID 0000-0002-3207-8211
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health & Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge CB1 8RN, UK.
Bartha Maria KnoppersCentre of Genomics and Policy, McGill University, Montreal, QC H3A 0G1, Canada.
Anna M ChiarelliDalla Lana School of Public Health, University of Toronto, Toronto, ON M5S 1A1, Canada.
Jacques SimardCHU de Québec-Université Laval Research Centre, Quebec City, QC G1S 4L8, Canada.

Funding

Cancer Research UK 20861CIHR 155865
6 · The paper itself

Abstract

In risk-stratified cancer screening, multiple risk factors are incorporated into the risk assessment. An individual's estimated absolute cancer risk is linked to risk categories with tailored screening recommendations for each risk category. Absolute risk, expressed as either remaining lifetime risk or shorter-term (five- or ten-year) risk, is estimated from the age at assessment. These risk estimates vary by age; however, some clinical guidelines (e.g., enhanced breast cancer surveillance guidelines) and ongoing personalised breast screening trials, stratify women based on absolute risk thresholds that do not vary by age. We examine an alternative approach in which the risk thresholds used for risk stratification vary by age and consider the implications of using age-independent risk thresholds on risk stratification. We demonstrate that using an age-independent remaining lifetime risk threshold approach could identify high-risk younger women but would miss high-risk older women, whereas an age-independent 5-year or 10-year absolute risk threshold could miss high-risk younger women and classify lower-risk older women as high risk. With risk misclassification, women with an equivalent risk level would be offered a different screening plan. To mitigate these problems, age-dependent absolute risk thresholds should be used to inform risk stratification.

Indexed as

absolute riskmisclassificationremaining lifetime riskrisk-stratified screeningrisk threshold

Identifiers

PMID34575693
PMCPMC8469877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.